These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 8635187)

  • 1. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide.
    Jiménez-Jiménez FJ; López-Alvarez J; Sánchez-Chapado M; Montero E; Miquel J; Sierra A; Gutiérrez F
    Clin Neuropharmacol; 1995 Jun; 18(3):277-9. PubMed ID: 8635187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease.
    Bilici A; Karadag B; Doventas A; Erdincler DS; Cetinkaya S; Ogut G; Tezcan V; Beger T
    Neth J Med; 2004 Nov; 62(10):389-92. PubMed ID: 15683095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis.
    Lund BC; Neiman RF; Perry PJ
    Pharmacotherapy; 1999 Dec; 19(12):1437-8. PubMed ID: 10600093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pergolide in Parkinson's disease: time for a change?
    Grosset KA; Grosset DG
    Lancet; 2004 Jun; 363(9424):1907-8. PubMed ID: 15183636
    [No Abstract]   [Full Text] [Related]  

  • 5. Pergolide-induced retroperitoneal fibrosis.
    Mondal BK; Suri S
    Int J Clin Pract; 2000; 54(6):403. PubMed ID: 11092116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
    Trifirò G; Morgante L; Tari M; Arcoraci V; Savica R
    J Am Geriatr Soc; 2008 Feb; 56(2):371-3. PubMed ID: 18251828
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and management of pergolide-induced fibrosis.
    Agarwal P; Fahn S; Frucht SJ
    Mov Disord; 2004 Jun; 19(6):699-704. PubMed ID: 15197712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pergolide-induced pleuropulmonary fibrosis.
    Bleumink GS; van der Molen-Eijgenraam M; Strijbos JH; Sanwikarja S; van Puijenbroek EP; Stricker BH
    Clin Neuropharmacol; 2002; 25(5):290-3. PubMed ID: 12410064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical hazards of the internet: gambling in Parkinson's disease.
    Larner AJ
    Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457
    [No Abstract]   [Full Text] [Related]  

  • 11. Sleep attacks and Parkinson's disease treatment.
    Ferreira JJ; Galitzky M; Montastruc JL; Rascol O
    Lancet; 2000 Apr; 355(9212):1333-4. PubMed ID: 10776750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide.
    Shaunak S; Wilkins A; Pilling JB; Dick DJ
    J Neurol Neurosurg Psychiatry; 1999 Jan; 66(1):79-81. PubMed ID: 9886458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ergoline-induced retroperitoneal fibrosis].
    Christoffersen CL; Siboni AH; Boisen E; Ladefoged C; Rasmussen C; Christensen-Dalsgaard S; Jakobsen P; Rasmussen LD; Schlander S
    Ugeskr Laeger; 2006 Apr; 168(17):1667; author reply 1667. PubMed ID: 16674890
    [No Abstract]   [Full Text] [Related]  

  • 15. [Sleep attacks and pergolide mesylate].
    García Ruiz PJ; Hernández J; Cantarero S; Fanjul S
    Neurologia; 2001 Feb; 16(2):92. PubMed ID: 11257938
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
    Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
    Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
    Senol MG; Togrol RE
    Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893
    [No Abstract]   [Full Text] [Related]  

  • 18. Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.
    Bares M; Rektorová I; Krajcovicová L; Rektor I
    J Neurol; 2008 Oct; 255(10):1596; author reply 1597. PubMed ID: 18758889
    [No Abstract]   [Full Text] [Related]  

  • 19. [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].
    van Strater AC; Bax JJ; van Hilten JJ; Jukema JW
    Ned Tijdschr Geneeskd; 2005 Apr; 149(16):891-4. PubMed ID: 15868996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisaccadic effects of a dopamine agonist as add-on therapy in advanced Parkinson's patients.
    Crevits L; Versijpt J; Hanse M; De Ridder K
    Neuropsychobiology; 2000; 42(4):202-6. PubMed ID: 11096336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.